Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
BMJ Open|December 4, 2024
Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort studySandra Jokšaitė, Robert Wood, Afisi Ismaila, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 19, 2023
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in EnglandGema Requena, Alexandrosz Czira, Victoria Banks, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 8, 2023
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in EnglandAlexandrosz Czira, Gema Requena, Victoria Banks, et al.
Respiratory Research|September 25, 2023
Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort studyAfisi S Ismaila, Kieran J Rothnie, Robert P Wood, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 21, 2023
Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in EnglandGema Requena, Alexandrosz Czira, Victoria Banks, et al.
Pulmonary Therapy|March 6, 2024
Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT StudyBhumika Aggarwal, Paul Jones, Alejandro Casas, et al.
Respiratory Research|November 1, 2019
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trialFrançois Maltais, Leif Bjermer, Edward M Kerwin, et al.
NPJ Primary Care Respiratory Medicine|May 26, 2021
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPDSandeep Bansal, Martin Anderson, Antonio Anzueto, et al.
ERJ Open Research|June 10, 2021
INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practiceDavid M G Halpin, Sally Worsley, Afisi S Ismaila, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 1, 2022
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID TrialDavid M G Halpin, Robyn Kendall, Soham Shukla, et al.
Pageof 8